Brugada syndrome: report of the second consensus conference.

By C. Antzelevitch, P. Brugada, M. Borggrefe, J. Brugada, R. Brugada, D. Corrado, I. Gussak, H. Lemarec, K. Nademanee, Andrés R Pérez Riera and 4 more. Heart Rhythm, 2005

2,076 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/e3e3a04a866e1b14a55311ddd4902020d312aa47

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. B. Maron
2. C. Semsarian
3. Mark S. Link
4. Rick A. Nishimura
5. C. Yancy
6. J. Towbin
7. J. Halperin
8. M. Creager

Citations in the corpus

• ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. (2008, background): “Patients with the Brugada syndrome have a structurally normal heart with a primary channelopathy (16,426).”
• Long-Term Prognosis of Patients Diagnosed With Brugada Syndrome: Results From the FINGER Brugada Syndrome Registry (2010, methodology): “defibrillator (ICD) was recommended (class II recommendation).(7) Several other studies, however, have failed to identify”
• Genome- and Phenome-Wide Analysis of Cardiac Conduction Identifies Markers of Arrhythmia Risk (2013, background): “In addition, a genetic disease caused by SCN5A loss-of-function mutations (Brugada syndrome) is characterized by slowed ventricular conduction and an increased risk for fatal arrhythmias.(34) Interestingly, previous analyses of variable PR duration have also identified strong associations with varia”
• European Resuscitation Council Guidelines 2021: Epidemiology of cardiac arrest in Europe. (2021, background): “depolarisation of myocytes, and medication-induced conditions that are associated with a reduced depolarisation reserve.(243) Other data”
• Recommendations for interpretation of 12-lead electrocardiogram in the athlete. (2009, background): “The Brugada syndrome is characterized by the typical ECG abnormalities and the increased vulnerability to ventricular fibrillation and SCD, in the absence of clinical evidence of structural heart disease.(105,106) In about one-fourth of cases, the syndrome has been linked to a genetic dysfunction of”
• HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. (2013, methodology): “There is general agreement that these patients should be protected with an ICD, irrespective of the presence of other risk factors [55].”
• HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). (2011, methodology): “Previous cardiac arrest and syncope put affected individuals at risk for recurrent (lethal) events.(86,87) The role of other parameters, including the outcome of invasive electrophysiogical studies, is disputed.”